Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBIT Margin (2020 - 2026)

Bioventus filings provide 6 years of EBIT Margin readings, the most recent being 12.34% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 733.0% to 12.34% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.5%, a 1215.0% increase, with the full-year FY2025 number at 9.5%, up 1215.0% from a year prior.
  • EBIT Margin hit 12.34% in Q4 2025 for Bioventus, up from 8.12% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 26.9% in Q2 2021 to a low of 98.58% in Q4 2022.
  • Median EBIT Margin over the past 5 years was 1.43% (2023), compared with a mean of 7.77%.
  • Biggest five-year swings in EBIT Margin: crashed -9762bps in 2022 and later surged 10058bps in 2023.
  • Bioventus' EBIT Margin stood at 2.42% in 2021, then tumbled by -414bps to 12.43% in 2022, then surged by 107bps to 0.86% in 2023, then surged by 483bps to 5.01% in 2024, then soared by 146bps to 12.34% in 2025.
  • The last three reported values for EBIT Margin were 12.34% (Q4 2025), 8.12% (Q3 2025), and 12.44% (Q2 2025) per Business Quant data.